Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

64.50EUR
16 Feb 2018
Change (% chg)

€1.00 (+1.57%)
Prev Close
€63.50
Open
€63.68
Day's High
€64.88
Day's Low
€63.57
Volume
3,675,375
Avg. Vol
2,523,320
52-wk High
€92.97
52-wk Low
€63.09

Select another date:

Fri, Feb 16 2018

BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​

* ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES

Oxford BioMedica wins second $100 million gene therapy contract

LONDON Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

Oxford BioMedica wins second $100 mln gene therapy contract

LONDON, Feb 15 Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

L'Oreal ready to buy Nestle stake in cosmetics leader

PARIS L'Oreal signalled its readiness to buy Nestle's 23 percent stake in the world's biggest cosmetics firm on Friday, which along with strong results lifted the French company's shares.

L'Oreal ready to buy shareholder Nestle's stake in the firm: CEO

PARIS L'Oreal stands ready to buy Nestle's 23 percent stake in the firm should its Swiss shareholder choose to sell, and it could finance a purchase through cash, by selling its Sanofi stake or by borrowing, L'Oreal's CEO said.

L'Oreal ready to buy shareholder Nestle's stake in the firm - CEO

PARIS, Feb 9 L'Oreal stands ready to buy Nestle's 23 percent stake in the firm should its Swiss shareholder choose to sell, and it could finance a purchase through cash, by selling its Sanofi stake or by borrowing, L'Oreal's CEO said.

BRIEF-Sanofi Commences Tender Offer For Acquisition Of Bioverativ

* SANOFI COMMENCES TENDER OFFER FOR ACQUISITION OF BIOVERATIV INC.

Sanofi's return to profit growth this year slower than hoped

PARIS Sanofi forecast on Wednesday a return to profit growth this year, but its shares fell as analysts had hoped for a bigger boost from recent deals and a revamped drugs pipeline.

Sanofi's return to profit growth this year slower than hoped

PARIS Sanofi forecast on Wednesday a return to profit growth this year, but its shares fell as analysts had hoped for a bigger boost from recent deals and a revamped drugs pipeline.

UPDATE 2-Drugmaker Sanofi sees return to profit growth this year

* Outlook disappoints, shares down 2 pct (Adds share price, comments, details)

Select another date: